← Back to Clinical Trials
Recruiting NCT06750497

NCT06750497 Forearm Immobilization in T2D

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06750497
Status Recruiting
Phase
Sponsor Wageningen University
Condition Healthy
Study Type INTERVENTIONAL
Enrollment 26 participants
Start Date 2024-11-21
Primary Completion 2027-04-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
Interventions
Forearm immobilization

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 26 participants in total. It began in 2024-11-21 with a primary completion date of 2027-04-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the present study is to assess the impact of short-term forearm immobilization on forearm muscle glucose uptake and amino acid net balance and kinetics in individuals with T2D compared with a control group with normoglycaemia.

Eligibility Criteria

Inclusion criteria * Males and females with or without diagnosed type 2 diabetes * Use lifestyle changes, metformin, gliclazide, or a combination thereof as oral glucose-lowering treatments for T2D * Aged 18-80 years at the time of signing informed consent * 18.5 ≥ BMI ≤ 35 kg·m2 Exclusion criteria * Type 1 or a genetic form of diabetes * Any diagnosed cardiovascular (heart) disease or high blood pressure (≥160 mmHg systolic and/or ≥100 mmHg diastolic) * Chronic use of any prescribed or over-the-counter pharmaceuticals (excluding oral contraceptives and contraceptive devices) that interact with muscle substrate metabolism (e.g. selective serotonin reuptake inhibitors) * Consumption of a low-carbohydrate diet * Smoking or chewing tobacco * Known anaemia * Regular use of dietary protein and/or amino acid supplements (\>3 times per week) * Currently involved in a structured progressive resistance training program (\>3 times per week) * A personal or family history of thrombosis (clots) * Any previous motor disorders or inborn errors in muscle and/or lipid metabolism * History of kidney disease * History of liver disease * Pregnant or breastfeeding * History of any drug or alcohol abuse in the past two years * Claustrophobia * Unable to give consent

Contact & Investigator

Central Contact

Marlou Dirks, PhD

✉ marlou.dirks@wur.nl

📞 +31 317 480 100

Frequently Asked Questions

Who can join the NCT06750497 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06750497 currently recruiting?

Yes, NCT06750497 is actively recruiting participants. Contact the research team at marlou.dirks@wur.nl for enrollment information.

Where is the NCT06750497 trial being conducted?

This trial is being conducted at Wageningen, Netherlands.

Who is sponsoring the NCT06750497 clinical trial?

NCT06750497 is sponsored by Wageningen University. The trial plans to enroll 26 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology